Glaxosmithkline Pharmaceuticals Ltd (GLAXO) — concall transcript | 30 June 2026
GlaxoSmithKline Pharmaceuticals reported 15% YoY sales growth to [amount context mismatch] crores in Q1 FY27, driven by 17% EBITDA growth and 24% PAT growth (27.6% margin), with innovation contributing 7% of revenue. General medicines, vaccines (especially Shingrix at 65% growth), and specialty products like oncology assets showed strong momentum, while rupee depreciation and one-time dividend impacts posed challenges. Management emphasized sustainable double-digit growth, targeting INR8,000 crores revenue in 4-5 years, and highlighted pipeline launches including Arexvy and Jemperli. Operating expenses rose 36% YoY due to front-loaded investments, but margins are expected to normalize to ~34%.
About Glaxosmithkline Pharmaceuticals Ltd (GLAXO)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when GLAXO files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track GLAXO — Free💡 Ask AI about this filing
📊 More GLAXO filings
- 🔴 Financial Results — 19 August 2026 GlaxoSmithKline Pharmaceuticals disclosed a tax refund of **₹4.99 crores** received on 18 August 202...
- 🟡 Voting Results — 13 August 2026 GlaxoSmithKline Pharmaceuticals Limited announced a postal ballot for shareholders to vote on two ke...
- 🟡 Board Meeting — 3 August 2026 The board approved unaudited standalone and consolidated financial results for Q1 ending June 2026, ...
- 🔴 Financial Results — 3 August 2026 GlaxoSmithKline Pharmaceuticals announced management changes effective 3rd August 2026, with Ms. Kar...
- 🟡 Board Meeting — 3 August 2026 GlaxoSmithKline Pharmaceuticals announced board meeting outcomes on August 3, 2026, including approv...
🔥 Also filed on 30 June 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when GLAXO files new disclosures
Track GLAXO filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track GLAXO — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd